<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874038</url>
  </required_header>
  <id_info>
    <org_study_id>21-5021</org_study_id>
    <nct_id>NCT04874038</nct_id>
  </id_info>
  <brief_title>Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)</brief_title>
  <official_title>Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled&#xD;
      trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing&#xD;
      the development of persistent pain 3-months after breast cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PLAN is a multicentre, parallel-group, blinded, randomized controlled trial of 1,150 patients&#xD;
      undergoing breast cancer surgery. Consented eligible patients will be randomized to receive&#xD;
      an intravenous lidocaine: 1.5 mg/kg bolus with induction of general anesthesia followed by a&#xD;
      2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).&#xD;
      Patients in the control group will receive a placebo bolus and infusion with normal saline&#xD;
      (0.9% sodium chloride solution). Study medications will be prepared in blinded 50 mL syringes&#xD;
      and labelled as per Regulatory requirements. Patients will follow up on the first 3 days&#xD;
      after surgery, and at 3 and 12-months postoperatively to report on pain, analgesic&#xD;
      consumption, functional, mood, and quality of life outcomes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of persistent pain 3-months after breast cancer surgery</measure>
    <time_frame>3- months</time_frame>
    <description>Persistent pain at 3-months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensities</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Pain intensities measured on the Numeric Rating Scale (NSR) at rest and movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Morphine-equivalent opioid consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate-to-severe persistent pain</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Defined as persistent pain with an NRS pain score of ≥4 at rest 24-hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent neuropathic pain</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Measured using the Douleur Neuropathique 4-symptoms interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory and affective qualities of pain</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Quality of pain is reported using the Short Form McGill Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional functioning</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Emotional functioning is reported using the Profile of Mood States (POMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Physical functioning measured by the interference scale of the Brief Pain Inventory-Short Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life quality of life</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Health-related quality of life will be assessed using EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Recurrence</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Cancer recurrence will be assessed as a secondary outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Adverse Events will be monitored as a secondary safety outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1150</enrollment>
  <condition>Post-mastectomy Pain Syndrome</condition>
  <condition>Breast Cancer</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Pain, Chronic</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative intravenous lidocaine/placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intraoperative intravenous lidocaine/placebo infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 20mg/ml</intervention_name>
    <description>Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lidocaine 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>0.9% sodium chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Undergoing a unilateral or bilateral lumpectomy or mastectomy, inclusive of all&#xD;
             pathologies, including prophylactic surgery (e.g., family history or BRCA gene&#xD;
             mutation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous breast surgery within 6 months of index surgery&#xD;
&#xD;
          2. Undergoing any autologous flap procedure during index surgery&#xD;
&#xD;
          3. Presence known chronic pain disorder involving surgical site or ipsilateral chest&#xD;
             wall, shoulder, or arm during the 3-months prior to index surgery&#xD;
&#xD;
          4. Documented hypersensitivity or allergy to lidocaine&#xD;
&#xD;
          5. Surgery not planned to be performed under general anesthesia and/or planned use of&#xD;
             regional or neuraxial anesthetic techniques before surgery (i.e., epidural,&#xD;
             paravertebral, serratus plane block, pectoralis or modified pectoralis block)&#xD;
&#xD;
          6. History of ventricular tachycardia, ventricular fibrillation, or atrioventricular&#xD;
             block without a pacemaker&#xD;
&#xD;
          7. Known cirrhotic liver disease&#xD;
&#xD;
          8. Pregnant&#xD;
&#xD;
          9. Unlikely to comply with follow-up (e.g. no fixed address, language difficulties that&#xD;
             would impede valid completion of questionnaires, plans to move out of town)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PJ Devereaux, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Gilron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kingston Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Khan</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3243</phone_ext>
    <email>James.Khan@medportal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nour Ayach</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>4221</phone_ext>
    <email>Nour.Ayach@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Khan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

